91results about "Cell membrane modification" patented technology

The present invention provides a method for safely and simply performing treatments such as exfoliation / floating treatment, dormancy treatment (dormancy not only enhances the protective effect but also suppresses unnecessary differentiation of cells, thereby maintaining an undifferentiated / low-differentiated state), and protective treatment for storage and transportation, on cells in tissue or cultured cells, while preventing their death and maintaining their viability, and a method for safely and simply performing cell activation treatment for implanting dormant floating cells. The cell treatment agent contains, as an active ingredient, at least one selected from alginic acid, heparins, sulfated dextran, and protease inhibitors.

Provided are a perfusion culture method and the like that are able to improve the productivity in the production of recombinant protein. Specifically, a method for improving recombinant protein production in perfusion culture of an animal cell having a capacity to produce a recombinant protein, the method comprising adding cystine and / or ammonium iron citrate to a cell culture medium, and the like, are provided.

The purpose of the present invention is to provide a novel coating film formation composition for the formation of a coating film having a function of inhibiting adhesion of a biological substance, a coating film using said composition, and manufacturing methods for a substrate for a cell culture, a multilayer film, and a cell aggregate using the coating film.　The present invention provides a coating film formation composition including: a polymer that includes structural units represented by formula (1) and formula (2) (in the formulas, R1-R3, X1, X2, T1, n1, n2, and n3 are as set forth in the specification and the claims) and that does not include a polysiloxane skeleton; and a solvent.

The invention relates to the technical field of biotechnology and immunotherapy, and discloses a method for inducing and amplifying pMHC specific homologous TSCM, which comprises the following steps: a) preparing pMHC presenting a single antigen peptide; b) sorting lymphocytes and mononuclear cells from a donor, and connecting the pMHC presenting the single antigen peptide obtained in the step a) to the surface of the separated mononuclear cells as stimulating cells; c) co-culturing the sorted lymphocytes serving as effector cells and stimulated cells in a culture medium containing a glycogen synthase kinase-3beta inhibitor, and inducing to generate pMHC specific homogeneous TSCM; and d) separating the pMHC specific homologous TSCM obtained in the step c). The method can induce and amplify sufficient pMHC specific homogeneous TSCM for adoptive immunotherapy, overcomes self tolerance and avoids or alleviates GVHD (Growth Vitamin Horse Disease); the preparation method is simple, induction and amplification efficiency is high, and universality and flexibility are achieved.

The invention belongs to the technical field of substance detection, and discloses a biomimetic nanomaterial coated with a cell membrane as well as a preparation method and application of the biomimetic nanomaterial. According to the invention, phospholipid functionalized magnetic nanoparticles are taken as a carrier, a cell membrane can be spontaneously integrated to the surface of the carrier by means of hydrophobic interaction, good binding capacity is achieved, and the obtained cell membrane-coated bionic nanomaterial is specifically alpha7nAChR-MNPs. According to the invention, a cell membrane for highly expressing an alpha7 nicotinic acetylcholine receptor is combined with phospholipid functionalized magnetic nanoparticles, so that alpha7nAChR-MNPs can specifically target potential risk substances, and the potential risk substances in a complex sample can be rapidly positioned and separated. The method is applied to food, potential risk substances can be predicted by simulating a biological recognition mechanism of a receptor, and the technical problems that a traditional screening method is insufficient in screening coverage degree, prone to causing misjudgment and missed judgment, high in cost and long in consumed time are solved.

The invention discloses an engineered exosome of LTH peptide modified miR-146a-5p and application, the core component of the medicine is the engineered exosome, and the engineered exosome is constructed by the following method: miR-146a-5p mimic infected human renal tubular epithelium HK2 cells with nucleotide sequences shown as SEQ ID NO.1-SEQ ID NO.2 are cultured and screened, the exosome rich in miR-146a-5p is separated from the culture supernatant of the cells, and the exosome rich in miR-146a-5p is obtained. Then, the kidney targeting peptide LTH is modified on the surface of the exosome. The invention reveals that HNRNP M protein is a key molecule for regulating and controlling miR-146a-5p to be sorted and enter the exosome for the first time, and verifies that the engineered exosome can be efficiently enriched in kidney, and by delivering miR-146a-5p to target IRAK1 gene in macrophage and inhibiting TRAF6 / IKK / NF-kappa B inflammation signal pathway, the macrophage is promoted to be polarized to a repairable M2 phenotype, so as to realize the purpose of improving the activity of the miR-146a-5p. And finally, the kidney injury induced by the calcium oxalate crystal is effectively relieved. The medicine has the advantages of clear mechanism, strong targeting property, good biocompatibility and the like, provides a brand new immunoregulation treatment strategy for renal injury, and has a wide clinical application prospect.

The present invention relates to processes and systems for preparing nanoparticles, cellular or viral membranes and / or cellular or viral membrane coated nanoparticles using or comprising, inter alia, a multi-inlet vortexing reactor, tangential flow filtration (TFF) and / or a high shear fluid processor such as a microfluidizer (or a microfluidizer processor). The present invention also relates to the nanoparticles, cellular or viral membranes and / or cellular or viral membrane coated nanoparticles prepared by the present processes and systems, and the uses and / or applications of the nanoparticles, cellular or viral membranes and / or cellular or viral membrane coated nanoparticles.

The present invention provides an oligodeoxynucleotide of unmethylated cytosine-phosphate-guanine dinucleotide and B lymphocytes bound thereto, which can target migration to diseased lymphoid organs and inhibit B lymphocytes activated under pathological conditions, thereby having a targeted therapeutic effect against pathological damage caused by B lymphocyte activation.

The present invention provides methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells. The present invention provides methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells.

The invention relates to a method for obtaining crystallised foetal bovine serum by adding agmatine that, at a specific concentration, acts to increase cell production and increase protein expression per cell. The method further relates to the specific form of reconstitution to liquid indicated in order to use same, without losing the original properties, allowing storage without an ultra-cold chain and reducing the risks of contamination, thereby allowing precise dosing of the amount to be used.

According to the targeting peptide and the engineered extracellular vesicle modified by the targeting peptide provided by the invention, the extracellular vesicle is modified by Pep-ACE2-2, so that the targeting property of the extracellular vesicle at an acute lung injury part is remarkably improved, and the acute lung injury is improved.

The present application relates to a kind of microcarrier and its application, the microcarrier has three-dimensional structure, the microcarrier has shell and inside is hollow or solid, the shell outer wall is uneven and has multiple concave points.This microcarrier improves the permeability of traditional microcarrier, is conducive to the material exchange between cell and external environment, improves cell survival rate, provides good mechanical protection for cell proliferation and constructs good three-dimensional structure for cell growth, realizes the friendly connection of cell, is conducive to the large-scale expansion of cell in limited space, and maintains the stability of cell physicochemical properties in long-term culture.

The invention discloses a modified exosome as well as a preparation method and application thereof, and relates to the technical field of biological medicines, CD44 targeted modification and composite active ingredients are synergistic to realize efficient repair of burn wounds and sensitive skin, and the modified exosome can be specifically enriched on the burn wounds or damaged sensitive skin parts through CD44 targeted peptide fragment coupling, so that the effect of repairing the burn wounds and the sensitive skin is achieved. The defects that a traditional repairing product is poor in targeting property and low in active ingredient utilization rate are overcome, the loaded dipotassium glycyrrhizinate, glutathione and FGF form a synergistic effect, wound healing and skin barrier repairing can be promoted through the FGF, the dipotassium glycyrrhizinate and the glutathione can be used for strongly resisting inflammation and oxidation, release of sensitive skin inflammatory factors is reduced, and the repairing effect is achieved. By matching with nitrogen protection incubation and a pulse ultrasonic loading process, the stability of active ingredients is greatly improved, finally, the repair effects that the healing process of burn wounds is remarkably accelerated, and sensitive skin percutaneous moisture loss is obviously reduced are achieved, and safety and effectiveness are both considered.

The invention discloses an engineered exosome for expressing a complete antibody and a preparation method of the engineered exosome, and belongs to the field of biotechnology and drug delivery. Aiming at the problem that a complete antibody is difficult to efficiently and stably express on the surface of an exosome membrane in the prior art, the engineering exosome with the complete antibody displayed on the surface is extracted from a culture supernatant after a target antibody and a natural antibody membrane-bound transmembrane region (TMD) sequence are fused, a recombinant lentiviral expression vector is constructed and a host cell is transfected. According to the method, TMD is used as an anchoring element, accurate positioning and efficient expression of an antibody on an exosome membrane are achieved, and the targeting recognition capacity of the exosome and the application potential of the exosome in the fields of targeting delivery, disease treatment and the like are remarkably improved. Experimental results show that the obtained exosome is typical in form, uniform in particle size and high in antibody expression efficiency, and a new technical scheme is provided for a targeting vector system based on the exosome.

Improved methods for large scale production of proteins and / or polypeptides in cell culture is provided. In accordance with the present invention, the method provides for culturing cells that have metabolically shifted. The use of such a method or system allows high levels of protein or polypeptide production and reduces accumulation of unwanted metabolic waste such as lactate. Proteins and polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, immunogenic, or other commercial biologic compositions, such as antibodies.

The present invention relates to extracellular vesicles having FGF21 linked to the surface thereof, and use thereof. The extracellular vesicles according to one embodiment can alleviate steatosis, reduce inflammation and fibrosis, and alleviate a decrease in bone density, which is a side effect occurring when FGF21 is used alone, and thus can be effectively used for preventing and treating liver diseases including metabolic abnormality-related steatohepatitis.

The invention discloses a reduction response type methionine prodrug, a liposome prepared from the reduction response type methionine prodrug and application of the reduction response type methionine prodrug. The invention relates to a reduction response type methionine prodrug, which structurally comprises two key units, namely disulfide bonds which respond to T cell activated membrane surface reducibility increase breakage to release methionine and hydrophobic tail chains which can form lipidosome. The prodrug is used for preparing a reduction response type methionine prodrug liposome, and then a metabolism enhancement type T cell drug is constructed. The cell medicine can reach a tumor part by utilizing the tropism of adoptive T cells to tumors, so that the anti-tumor effect of the adoptive T cells is enhanced, the immunosuppression microenvironment is relieved, the exhaustion of endogenous T cells is further reversed, and the space-time specific metabolism intervention of the T cells in the microenvironment is realized.

The invention relates to the technical field of biomedical treatment, and discloses a cell sorting and culturing method and device, computer equipment and a storage medium. The cell sorting and culturing method comprises the following steps: separating a sample solution by using a density gradient centrifugation method to obtain a to-be-cultured cell solution; conveying the to-be-cultured cell sap into culture equipment through first pipeline switching operation, and performing culture treatment on the to-be-cultured cell sap to obtain cultured cell sap; and obtaining a culture cell sap through a second switching pipeline operation, and concentrating and cleaning the culture cell sap to obtain a target cell sap. According to the invention, a totally-enclosed one-stop sterile operation environment can be ensured, the pollution risk during cell operation site change is avoided, and the cell treatment stability is improved. Meanwhile, continuous operation between sorting and culture treatment of the cell sap can be achieved through two times of pipeline switching operation, the automation degree and continuity of cell treatment are improved, the operation time is saved, and the cell treatment efficiency is improved.

To provide a fusion protein that can be used to modify mitochondria.SOLUTION: There is provided a fusion protein comprising a mitochondrial outer membrane anchoring peptide and a desired pharmacological protein, in order to prepare modified mitochondria with a foreign protein bound to the outer membrane of the mitochondria. There is also provided a fusion protein comprising an antibody or a fragment thereof and a mitochondrial outer membrane anchoring peptide.SELECTED DRAWING: None

The invention relates to a genetically engineered bacterium and application thereof, a culture method of the genetically engineered bacterium and a pharmaceutical composition, and belongs to the technical field of tumor treatment. The invention provides a genetically engineered bacterium. The genetically engineered bacterium is composed of tumor vesicles and a thallus body, the tumor vesicles are connected with the thallus body through distearoyl phosphatidyl acetamide-N-polyethylene glycol 2000-hydroxysuccinimide, and the tumor vesicles are connected with the thallus body through distearoyl phosphatidyl acetamide- The thallus body comprises an overexpression vector of D-mannose isomerase; the engineering bacterium expresses D-mannose isomerase in an environment with oxygen volume concentration of 0-12%. The engineering bacterium of tumor microenvironment hypoxia induced mannose loaded with tumor cell membrane vesicles, constructed by the invention, can improve the in-vivo treatment effect of adoptive T cells.

The present invention relates to methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells.

The present disclosure provides a surface modified immune cell comprising (i) a linker that is covalently bound to an immune cell surface and (ii) a non-antibody ligand covalently bound to said linker, wherein said ligand is selective to a receptor that is present in a target cell. The present disclosure also provides a method for producing and using the same.

Provided is a method for acquiring mammalian embryos having a high fecundation rate by culturing fertilized mammalian ova under suitable conditions.　The fertilized mammalian ova are cultured using a culture medium containing a glycine metabolism-related substance to acquire the embryos.

The invention belongs to the technical field of regenerative medicine and targeted drug delivery, and particularly relates to mesenchymal stem cells with lung first-pass escape and inflammation homing dual functions and a preparation method and application thereof. The mPEG-DSPE is inserted into a cell membrane to form a hydrophilic shell, so that the cell rigidity is remarkably reduced, endogenous adhesion molecules are shielded, the lung first-pass effect problem of intravenous infusion of MSC is effectively solved, and the lung retention rate is reduced from 60-80% to 35% or below. Through covalent grafting of the targeting peptide, the cells are endowed with active homing ability, a selective homing behavior is presented on VCAM-1 high-expression inflammation tissues under physiological shearing force, and precise targeting therapy is achieved.

The present invention relates to the use of PEG-phospholipid molecules to selectively mask surface antigens on red blood cells, platelets and / or endothelial cells, whereby blood products treated with PEG-phospholipid molecules can be infused into cross-incompatible or non-compatible recipients with reduced risk of antibody binding to surface antigens and aggregation. Correspondingly, organ grafts treated with PEG-phospholipid molecules can be transplanted into cross-incompatible or non-compatible recipients with reduced risk of antibody binding and antibody-mediated rejection.

The present invention relates to a method for the in vitro large-scale expansion of double-negative T cells rich in Tscm and Tem. Specifically, the method comprises the step of: (a) providing an initial sample I of peripheral blood obtained from a donor, (b) pretreating the initial sample I to obtain sample II, and (c) culturing sample II in a culture system containing a culture medium suitable for the growth of DNT cell, thereby obtaining a sample III. The expansion process of the present invention is simple and stable, and can achieve the in vitro large-scale culturing of DNT cells rich in Tscm and Tcm cell characteristics. The purity of the final product DNT cells (CD3+CD4−CD8−) is ≥85%, which meets the requirements for clinical use.

The present invention relates to a novel chimeric adapter protein and an extracellular vesicle containing the same, and more particularly, to a novel chimeric adapter protein and an extracellular vesicle containing the same, according to one aspect, the chimeric adapter protein can be abundantly expressed on the surface of the extracellular vesicle, has excellent binding efficiency, and does not interact with other components on the surface of the extracellular vesicle, thereby maintaining the integrity of the extracellular vesicle, etc. Good bioavailability and modularization are realized. When the medicine is loaded in the extracellular vesicles, the extracellular vesicles can also be used as an effective nano-carrier.

The invention discloses a reduction responsive nanoparticle armed chimeric antigen receptor T cell and a preparation method and application thereof, and belongs to the technical field of antigen receptor T cells, the chimeric antigen receptor T cell comprises a T cell expressing a chimeric antigen receptor aiming at a tumor-associated antigen; the plurality of reduction responsive hybrid nanoparticles are fixed on the outer surface of the T cell; according to the invention, the drug delivery system is accurately enriched at the tumor part by utilizing the targeting property of the CAR T cells to the tumor, and the release of the nanoparticles depends on a reducing microenvironment generated on the surface after the CAR T cells are activated, so that the fixed-point and controllable release of the drug is realized, and the toxic and side effects of systematic drug delivery are greatly reduced.

The invention discloses a preparation method and application of a novel macrophage for treating myocardial infarction, and belongs to the fields of cell engineering, nanotechnology, material science, immunology and the like. According to the invention, bone marrow-derived macrophages are induced to be polarized to M2 type and are subjected to magnetic modification, so that the macrophages are endowed with the capability of efficiently expressing vascular endothelial growth factors, Mag M2-M-VEGF cells are obtained, and proliferation of endothelial cells and formation of collateral vessels are promoted through local high expression of VEGF at a myocardial infarction part, so that local ischemia injury is relieved. According to the invention, precise targeted delivery of cells is realized, local inflammatory response is inhibited, and blood perfusion in an infarction area is improved. The medicine is endowed with magnetic targeting capacity by internalizing Fe3O4 NPs and is accurately enriched in myocardial infarction tissue under the guidance of a magnetic field, M2 type polarization inhibits pro-inflammatory reaction by reducing pro-inflammatory factor release and releasing a large amount of anti-inflammatory factors, and meanwhile, VEGF is specifically secreted, angiogenesis of an infarction part is promoted, and the capillary density of an infarction region is effectively increased.

The invention discloses a method for constructing an antibody-gamma delta T cell conjugate by using a chemical engineering method. The method comprises the following steps: carrying out metabolism labeling on glycan on the surface of a gamma delta T cell by utilizing a rapid metabolism glycan labeling strategy, and coupling a functionalized modified antibody with the labeled gamma delta T cell through click chemistry to construct the antibody-gamma delta T cell conjugate. Experiments show that the conjugate constructed by the method has remarkable killing activity on PD-L1 positive tumor cells, and a new effective strategy is provided for tumor treatment.